Aufgrund der neuen rechtlichen Situation für Online-Plattformen wurde das Forum am 15.02.24 geschlossen. Das Projekt selber wird intern weitergeführt. Infos hier: KLICK

Endlich! Annahme des ICD-Codes! Lest hier: KLICK

Informationen zum ICD-Code gibt es hier (Englisch): KLICK

Achtung! Der erste FC Awareness Day am 22.10.2024. INFOS HIER: KLICK

Kohortenstudie “Fluoroquinolones collagen adverse events, 2015”: 2.1% tendon ruptures

Benutzeravatar
Schorsch
Site Admin
Site Admin
Beiträge: 1270
Registriert: 07.10.2016, 09:36

Kohortenstudie “Fluoroquinolones collagen adverse events, 2015”: 2.1% tendon ruptures

#310

Beitragvon Schorsch » 24.01.2017, 21:27

Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study.

Quelle: http://bmjopen.bmj.com/content/5/11/e010077.full
weiter Informationen und Diagramme über Link einsehbar.

Nick Daneman1,2,3,4,
Hong Lu1,
Donald A Redelmeier1,2,3,5

Author affiliations


Abstract

Objectives Fluoroquinolone-associated tendon ruptures are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of fluoroquinolones and tendon rupture, to clarify the potential association of fluoroquinolones and retinal detachment, and to test for a potentially lethal association between fluoroquinolones and aortic aneurysms.


Setting Population-based longitudinal cohort study in Ontario, Canada.

Participants Older adults turning 65 years between April 1 1997 and March 31 2012 were followed until primary outcome, death, or end of follow-up (March 31 2014). Fluoroquinolone prescriptions were measured as a time-varying covariate, with patients considered at risk during and for 30 days following a treatment course.

Primary outcome measures Severe collagen-associated adverse events defined as tendon ruptures, retinal detachments and aortic aneurysms diagnosed in hospital and emergency departments.

Results Among the 1 744 360 eligible patients, 657 950 (38%) received at least one fluoroquinolone during follow-up, amounting to 22 380 515 days of treatment. The patients experienced 37 338 (2.1%) tendon ruptures, 3246 (0.2%) retinal detachments, and 18 391 (1.1%) aortic aneurysms. Severe collagen-associated adverse events were more common during fluoroquinolone treatment than control periods, including tendon ruptures (0.82 vs 0.26/100-person years, p<0.001), retinal detachments (0.03 vs 0.02/100-person-years, p=0.003) and aortic aneurysms (0.35 vs 0.13/100-person-years, p<0.001). Current fluoroquinolones were associated with an increased hazard of tendon rupture (HR 3.13, 95% CI 2.98 to 3.28; adjusted HR 2.40, 95% CI 2.24 to 2.57) and an increased hazard of aortic aneurysms (HR 2.72, 95% CI 2.53 to 2.93; adjusted HR2.24, 95% CI 2.02 to 2.49) that were substantially greater in magnitude than the association of these outcomes with amoxicillin. The hazard of retinal detachment was marginal (HR 1.28, 95% CI 0.99 to 1.65; adjusted HR 1.47, 95% CI 1.08 to 2.00) and not greater in magnitude than that observed with amoxicillin.

Conclusions Fluoroquinolones are associated with subsequent tendon ruptures and may also contribute to aortic aneurysms.


http://dx.doi.org/10.1136/bmjopen-2015-010077
Levofloxacin zwei Tage je 500 mg Kapsel im Juli 2015

Zurück zu „Div. Fakten / Informationen / Studien“

Wer ist online?

Mitglieder in diesem Forum: 0 Mitglieder und 0 Gäste